- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT00524316
Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
A Phase II Study of SUNITINIB MALATE (Sutent) and Chemoembolization in Patients With Unresectable Hepatocellular Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs, such as doxorubicin, near the tumor. Giving sunitinib together with chemoembolization may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving sunitinib together with chemoembolization works in treating patients with liver cancer that cannot be removed by surgery.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Yksityiskohtainen kuvaus
OBJECTIVES:
Primary
- To determine the progression-free survival at 4 months of patients treated with this regimen.
Secondary
- To determine overall survival of these patients.
- To determine if dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can be used to measure decrease in tumor perfusion and vascular permeability as a result of treatment with sunitinib malate in combination with TACE, and if it can be useful in prognosis.
- To examine the safety and tolerability of this regimen.
- To determine if a change in circulating endothelial precursor cell number and total monocyte count on days 3, 8, 10, and 35 of therapy (as compared with levels at baseline) and decrease in soluble vascular endothelial growth factor receptor-2 in serum on days 8 (before TACE), 10, and 35 of therapy (as compared with baseline) correlate with improved response and survival.
- To determine the effect of this therapy on quality of life as measured by the FACT-HEP scale prior to each course of therapy.
OUTLINE: This is a multicenter study.
Patients receive oral sunitinib malate once daily on days 1-7 and 15-35 in course 1 and on days 1-28 in all subsequent courses. Patients undergo hepatic artery chemoembolization with doxorubicin hydrochloride on day 8 of course 1 only. Treatment with sunitinib malate repeats every 6 weeks* in the absence of disease progression or unacceptable toxicity.
NOTE: *Course 1 is 7 weeks in duration; all subsequent courses are 6 weeks in duration.
Blood samples are collected at baseline and periodically during study to measure circulating endothelial precursor cell levels, total monocyte count, and soluble vascular endothelial growth factor receptor-2.
Quality of life is assessed by the FACT-HEP scale at baseline, prior to each course of treatment, and then at the completion of treatment.
After completion of study treatment, patients are followed every 6 months.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Opiskelupaikat
-
-
New York
-
Buffalo, New York, Yhdysvallat, 14263-0001
- Roswell Park Cancer Institute
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
DISEASE CHARACTERISTICS:
Histologically, cytologically, or serologically* confirmed hepatocellular carcinoma meeting the following criteria:
- 1-4 lesions
- Involvement of 1 or both liver lobes NOTE: *Alpha-fetoprotein (AFP) > 500 mcg/L in high-risk patients
Measurable disease by CT scan or MRI
- Disease does not exceed 50% of the liver parenchyma
- At least 1 lesion ≥ 3 cm in longest diameter
- Tumor burden involves < 50% of the liver
Refused surgery OR unresectable disease due to any of the following:
- Multifocality
- Advanced cirrhosis
- Comorbid illness
- Candidate for chemoembolization
- No fibrolamellar histology
- No ascites
- No known brain metastases
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Life expectancy ≥ 12 weeks
- WBC ≥ 3,000/mm³
- ANC ≥ 1,500/mm³
- Hemoglobin ≥ 8.5 g/dL (transfusion allowed)
- Platelet count ≥ 100,000/mm³
- Bilirubin ≤ 2 mg/dL
- AST ≤ 5 times upper limit of normal (ULN)
- INR < 1.5
- Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 30 mL/min
- No bleeding diathesis or coagulopathy
- No active congestive heart failure
- No uncontrolled angina
- No myocardial infarction within the past 12 months
- No cardiac arrhythmia
- Ejection fraction ≥ 45% (in patients with known coronary artery disease and in patients > 50 years of age)
- Child-Pugh class A or B cirrhosis
- No impedance of hepatopedal blood flow (portal vein thrombosis)
- No thrombosis of the main portal vein
- No encephalopathy
- No biliary obstruction
- No variceal bleed within the past 6 months
- No history of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib malate
- No absolute contraindication to doxorubicin, iodinated contrast material, microfibrillar collage hemostat, or dexamethasone
No other concurrent uncontrolled illness including, but not limited to, any of the following:
- Ongoing or active infection
- Psychiatric illness or social situation that would limit compliance with study requirements
- No other active malignancies within the past year except nonmelanoma skin cancer or carcinoma in situ
- No significant traumatic injury within the past 4 weeks
- No QTc prolongation (i.e., QTc interval ≥ 500 msec) or other significant ECG abnormalities
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 6 months after the completion of study treatment
PRIOR CONCURRENT THERAPY:
- Recovered from prior therapy
Prior liver-directed therapy, such as chemoembolization, radiofrequency ablation, cryoablation, or ethanol injection allowed if the following criteria are met:
- Treated lesion remains inactive by CT scan or MRI and new lesion being embolized is distinct from the previously treated lesion
- Radiographic progression of previously treated lesion requiring re-embolization
- Prior liver resection allowed
- Prior immunotherapy allowed
- No prior antiangiogenesis therapy
No prior liver transplantation
- Patients awaiting a cadaveric or orthotopic liver transplantation are eligible provided they have end-stage liver disease with a priority score of < 20 points
- More than 4 weeks since prior radiotherapy or chemotherapy (6 weeks for nitrosoureas or mitomycin C)
- More than 4 weeks since prior major surgery or open biopsy
- At least 1 week since prior fine needle biopsy
- No concurrent immunotherapy
- No concurrent radiotherapy
- No concurrent combination antiretroviral therapy for HIV-positive patients
No concurrent therapeutic doses of coumarin-derivative anticoagulants (e.g., warfarin)
- Doses of ≤ 1 mg/day are allowed for prophylaxis of thrombosis as long as INR ≤ 1.5
- Both full dose and prophylactic dose low molecular weight heparin allowed as long as PT INR ≤ 1.5
- No anticipated major surgery during and for 3 months after completion of study treatment
- No other concurrent investigational agents
- No other concurrent anticancer therapy
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Sunitinib
oral sunitinib malate once daily on days 1-7 and 15-35 in course 1 and on days 1-28 in all subsequent courses
|
Korrelatiivinen tutkimus
Correlative Study
Transarterial chemoembolization
Given Orally
Surgical procedure
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Progression-free Survival
Aikaikkuna: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
median progression free survival in months
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Overall Survival
Aikaikkuna: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
median survival in months
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
Tissue Perfusion, Ktrans, IAUC, and Percent Viable Tumor as Measured by DCE-MRI at Baseline and on Days 8 (Before Transarterial Chemoembolization), 10, and 35
Aikaikkuna: Baseline, day 8, day 10, day 28 and day 35
|
Baseline, day 8, day 10, day 28 and day 35
|
|
Safety and Tolerability
Aikaikkuna: Daily while on treatment through study completion, an average of 1 year
|
Number of participants with adverse advent. Please refer to adverse event reporting for more detail. |
Daily while on treatment through study completion, an average of 1 year
|
Assess the Change in the Quality of Life Among Patients Using the FACTHep (Version 4) for Hepatobiliary Cancers.
Aikaikkuna: Baseline and Cycle 2
|
We utilized the FACT-HEP TOTAL SCORE (version 4) quality-of-life scale, which is a 45 item scale ranging from 96-178. Higher scores reflect better quality of life. No subscales were analyzed. |
Baseline and Cycle 2
|
Tumor Marker Response (AFP)
Aikaikkuna: Baseline, week 7 and every 6 weeks after
|
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
|
Baseline, week 7 and every 6 weeks after
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Renuka Iyer, MD, Roswell Park Cancer Institute
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Ruoansulatuskanavan sairaudet
- Neoplasmat
- Neoplasmat sivustoittain
- Ruoansulatuskanavan kasvaimet
- Maksasairaudet
- Maksan kasvaimet
- Huumeiden fysiologiset vaikutukset
- Farmakologisen vaikutuksen molekyylimekanismit
- Entsyymin estäjät
- Antineoplastiset aineet
- Topoisomeraasi II:n estäjät
- Topoisomeraasin estäjät
- Angiogeneesin estäjät
- Angiogeneesiä moduloivat aineet
- Kasvuaineet
- Kasvun estäjät
- Proteiinikinaasin estäjät
- Antibiootit, antineoplastiset
- Sunitinib
- Doksorubisiini
- Liposomaalinen doksorubisiini
Muut tutkimustunnusnumerot
- CDR0000563261
- RPCI-I-82706
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Maksa syöpä
-
Fore BiotherapeuticsRekrytointiCancer sisältää BRAF-muutoksiaYhdysvallat, Saksa, Espanja, Yhdistynyt kuningaskunta, Ranska, Korean tasavalta, Italia, Ruotsi, Kanada
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)ValmisLymfaödeema | Perioperatiiviset/postoperatiiviset komplikaatiot | Vaiheen II Vulvar Cancer AJCC v7 | Vaihe IIIA Vulvar Cancer AJCC v7 | Vaihe IIIB Vulvar Cancer AJCC v7 | Vaihe IIIC Vulvar Cancer AJCC v7 | Stage IVA Vulvar Cancer AJCC v7 | Vaihe IA Vulvar Cancer AJCC v7 | Vaihe IB Vulvar Cancer AJCC v7 | Vaihe...Yhdysvallat
-
Samsung Medical CenterValmisHER2-positiivinen Refractory Advanced CancerKorean tasavalta
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Aktiivinen, ei rekrytointiVaiheen III vulvar Cancer AJCC v7 | Vaihe IIIA Vulvar Cancer AJCC v7 | Vaihe IIIB Vulvar Cancer AJCC v7 | Vaihe IIIC Vulvar Cancer AJCC v7 | Epäsuoran levyepiteelisyöpä | Stage IVA Vulvar Cancer AJCC v7Yhdysvallat
-
Grand Valley State UniversityIlmoittautuminen kutsustaMetaboliseen aineenvaihduntaan liittyvä dysfunction Steatotic Liver Disease (MASLD) | Aineenvaihduntaan liittyvä steatohepatiitti (MASH)Yhdysvallat
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RekrytointiVaiheen II Vulvar Cancer AJCC v8 | Vaiheen IIIC vulvar Cancer AJCC v8 | Stage IVA Vulvar Cancer AJCC v8 | Kolmannen vaiheen ulkosynnyttäjäsyöpä AJCC v8 | Vaihe IIIA Vulvar Cancer AJCC v8 | Vaihe IIIB Vulvar Cancer AJCC v8Yhdysvallat
-
University of UtahNational Cancer Institute (NCI)RekrytointiVäsymys | Istuva elämäntapa | Metastaattinen eturauhassyöpä | Stage IV Prostate Cancer AJCC (American Joint Committee on Cancer) v8 | Stage IVA Eturauhassyöpä AJCC (American Joint Committee on Cancer) v8 | Stage IVB Eturauhassyöpä AJCC (American Joint Committee on Cancer) v8Yhdysvallat
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...ValmisTutki kiinalaisia naisia, jotka eivät ole noudattaneet American Cancer Societyn mammografiaseulontaohjeitaYhdysvallat
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)ValmisOhutsuolen adenokarsinooma | Vaihe III ohutsuolen adenokarsinooma AJCC v8 | Vaihe IIIA ohutsuolen adenokarsinooma AJCC v8 | Vaihe IIIB ohutsuolen adenokarsinooma AJCC v8 | IV vaiheen ohutsuolen adenokarsinooma AJCC v8 | Vater-adenokarsinooman ampulla | Vaiheen III ampulla Vater Cancer AJCC v8 | Vaiheen... ja muut ehdotYhdysvallat
-
Centre Francois BaclesseLigue contre le cancer, FranceRekrytointiPitkäaikaiset syövän sivuvaikutukset | Tukihoito syövän hoidossa | Cancer Survivorship Care Plan | Edistynyt sairaanhoitaja | Lantion gynekologinen syöpäRanska
Kliiniset tutkimukset laboratoriobiomarkkerianalyysi
-
ORIOL BESTARDValmisMunuaisensiirto | CMV-infektioEspanja, Belgia
-
Mologic LtdUniversity College London Hospitals; Innovate UKTuntematon
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)Ei vielä rekrytointiaHIV-infektiot | B-hepatiitti
-
Sonde HealthMontefiore Medical CenterAktiivinen, ei rekrytointi
-
University of MichiganNational Institute on Aging (NIA)Ilmoittautuminen kutsustaAlzheimerin tauti | Lievä kognitiivinen heikentyminen | Amnestinen lievä kognitiivinen häiriöYhdysvallat
-
Boston University Charles River CampusNational Institute on Deafness and Other Communication Disorders (NIDCD)Rekrytointi
-
US Department of Veterans AffairsValmisKielihäiriöt | Afasia | PuhehäiriötYhdysvallat
-
Liao Jian AnRekrytointiPään ja kaulan syöpäTaiwan
-
Istituto per la Ricerca e l'Innovazione BiomedicaRekrytointi
-
University of VirginiaTuntematon